New enzyme therapy for fabry disease tested in Real-World setting
Disease control
Ongoing
This study follows 60 adults with Fabry disease who are receiving pegunigalsidase-alfa, a newer enzyme replacement therapy. Researchers want to see how well it works in everyday medical practice, especially for kidney function. Participants will be treated for 2 years at speciali…
Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC